Pirenzepine: Difference between revisions
Kiran Singh (talk | contribs) No edit summary |
Kiran Singh (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{drugbox | IUPAC_name =11-[(4-Methylpiperazin-1yl)acetyl]6,11-dihydro-5''H''-pyrido[2,3-''b''][1,4]benzodiazepin-6-on| image = Pirenzepine.png | width = 221 | CAS_number = 28797-61-7 | ATC_prefix = A02 | ATC_suffix = BX03 | ATC_supplemental = | PubChem = 4848 | DrugBank = APRD00515 | C=19 | H=21 | N=5 | O=2 | molecular_weight = 351.403 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} | {{drugbox | IUPAC_name =11-[(4-Methylpiperazin-1yl)acetyl]6,11-dihydro-5''H''-pyrido[2,3-''b''][1,4]benzodiazepin-6-on| image =Pirenzepine.png | width = 221 | CAS_number = 28797-61-7 | ATC_prefix = A02 | ATC_suffix = BX03 | ATC_supplemental = | PubChem = 4848 | DrugBank = APRD00515 | C=19 | H=21 | N=5 | O=2 | molecular_weight = 351.403 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} | ||
__Notoc__ | __Notoc__ | ||
{{SI}} | {{SI}} | ||
Latest revision as of 14:47, 9 April 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H21N5O2 |
| Molar mass | 351.403 g/mol |
|
WikiDoc Resources for Pirenzepine |
|
Articles |
|---|
|
Most recent articles on Pirenzepine Most cited articles on Pirenzepine |
|
Media |
|
Powerpoint slides on Pirenzepine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pirenzepine at Clinical Trials.gov Clinical Trials on Pirenzepine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pirenzepine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pirenzepine Discussion groups on Pirenzepine Patient Handouts on Pirenzepine Directions to Hospitals Treating Pirenzepine Risk calculators and risk factors for Pirenzepine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pirenzepine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pirenzepine (marketed by Merck Marker under the trade-name Gastrozepin) is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as Muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), the result being an increase in gastric motility and digestion. It has no effects on the brain and spinal cord as it cannot diffuse through the blood-brain barrier.
Pirenzepine has been investigated for use in myopia control.[1]
References
- ↑ Czepita D (2005). "Fundamentals of modern treatment of myopia". Ann Acad Med Stetin. 51 (2): 5–9. PMID 16519089.
Template:Pharma-stub Template:Drugs for peptic ulcer and GORD
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drug
- Muscarinic antagonists